Annual CFF
$234.29 M
+$236.09 M+13123.12%
December 31, 2023
Summary
- As of February 7, 2025, ELVN annual cash flow from financing activities is $234.29 million, with the most recent change of +$236.09 million (+13123.12%) on December 31, 2023.
- During the last 3 years, ELVN annual CFF has risen by +$103.77 million (+79.51%).
- ELVN annual CFF is now at all-time high.
Performance
ELVN Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$1.12 M
-$689.00 K-38.15%
September 30, 2024
Summary
- As of February 7, 2025, ELVN quarterly cash flow from financing activities is $1.12 million, with the most recent change of -$689.00 thousand (-38.15%) on September 30, 2024.
- Over the past year, ELVN quarterly CFF has dropped by -$89.15 million (-98.76%).
- ELVN quarterly CFF is now -99.53% below its all-time high of $237.44 million, reached on March 31, 2023.
Performance
ELVN Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$93.28 M
+$1.54 M+1.68%
September 30, 2024
Summary
- As of February 7, 2025, ELVN TTM cash flow from financing activities is $93.28 million, with the most recent change of +$1.54 million (+1.68%) on September 30, 2024.
- Over the past year, ELVN TTM CFF has increased by +$6.17 million (+7.08%).
- ELVN TTM CFF is now -60.34% below its all-time high of $235.23 million, reached on March 31, 2023.
Performance
ELVN TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
ELVN Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +10000.0% | -98.8% | +7.1% |
| 3 y3 years | +79.5% | -99.5% | -60.3% |
| 5 y5 years | +79.5% | -99.5% | -60.3% |
ELVN Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | >+9999.0% | -99.5% | +139.6% | -60.3% | +5285.3% |
| 5 y | 5-year | at high | >+9999.0% | -99.5% | +139.6% | -60.3% | +5285.3% |
| alltime | all time | at high | >+9999.0% | -99.5% | +139.6% | -60.3% | +5285.3% |
Enliven Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $1.12 M(-38.2%) | $93.28 M(+1.7%) |
| Jun 2024 | - | $1.81 M(-98.0%) | $91.74 M(+5.3%) |
| Mar 2024 | - | $90.27 M(>+9900.0%) | $87.11 M(-62.8%) |
| Dec 2023 | $234.29 M | $90.00 K(-121.2%) | $234.29 M(+1.1%) |
| Sep 2023 | - | -$425.00 K(-84.9%) | $231.82 M(-0.3%) |
| Jun 2023 | - | -$2.82 M(-101.2%) | $232.41 M(-1.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2023 | - | $237.44 M(<-9900.0%) | $235.23 M(<-9900.0%) |
| Dec 2022 | -$1.80 M(+77.1%) | -$2.38 M(-1549.4%) | -$1.80 M(-411.2%) |
| Sep 2022 | - | $164.00 K(+3180.0%) | $578.00 K(+39.6%) |
| Jun 2022 | - | $5000.00(-98.8%) | $414.00 K(+1.2%) |
| Mar 2022 | - | $409.00 K | $409.00 K |
| Dec 2021 | -$1.02 M(-100.8%) | - | - |
| Dec 2020 | $130.51 M | - | - |
FAQ
- What is Enliven Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Enliven Therapeutics?
- What is Enliven Therapeutics annual CFF year-on-year change?
- What is Enliven Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Enliven Therapeutics?
- What is Enliven Therapeutics quarterly CFF year-on-year change?
- What is Enliven Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Enliven Therapeutics?
- What is Enliven Therapeutics TTM CFF year-on-year change?
What is Enliven Therapeutics annual cash flow from financing activities?
The current annual CFF of ELVN is $234.29 M
What is the all time high annual CFF for Enliven Therapeutics?
Enliven Therapeutics all-time high annual cash flow from financing activities is $234.29 M
What is Enliven Therapeutics annual CFF year-on-year change?
Over the past year, ELVN annual cash flow from financing activities has changed by +$236.09 M (+13123.12%)
What is Enliven Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of ELVN is $1.12 M
What is the all time high quarterly CFF for Enliven Therapeutics?
Enliven Therapeutics all-time high quarterly cash flow from financing activities is $237.44 M
What is Enliven Therapeutics quarterly CFF year-on-year change?
Over the past year, ELVN quarterly cash flow from financing activities has changed by -$89.15 M (-98.76%)
What is Enliven Therapeutics TTM cash flow from financing activities?
The current TTM CFF of ELVN is $93.28 M
What is the all time high TTM CFF for Enliven Therapeutics?
Enliven Therapeutics all-time high TTM cash flow from financing activities is $235.23 M
What is Enliven Therapeutics TTM CFF year-on-year change?
Over the past year, ELVN TTM cash flow from financing activities has changed by +$6.17 M (+7.08%)